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Use of Biological Markers and
Pharmacokinetics in Human Health
RiskAssessment
by Dale Hattis*
Therearetworeasonstoconnectdiscussionsofbiolo a markersandphacokinetics. irst,bothtendtoopenup
theblackboxbetweenexposureandeffect.Doingthi promisesmorecomplete ndingthansimpleinput-
outputanalysis, thepossibility ofbettermechanim-basedprojectionofriskbeyondtherangeofpossibledirectobser-
vations,andthepossibilityofgreatersensitivity ofanalysis, insomecasesgoingfromtheor tothecellastheunit
ofanalysis. Second, pharmacokinetic (orsimlnarpharmacodynamic)analysiswilloftenbeessentialforappropriatein-
terpretationofbiologia markerinformation. Oneneedssomesortofdynamicmodelofthegenerationandlossofthe
markerinrelationtoexposureinordertouseabiologicalmarker,eithertoformabettermeasureofdosage(eitherac-
cumulated past dose, orbiologically relevantdose), ortomakeanimprovedpreditionofeffect. (Foreample, the use
ofabloodc levelalonetopditkidneyeffectsmightbeinfriorto e ns basedon pastaccumu-
tionof uminthekidny, basedonthepthistoryofc I blodleve x time).Severaleampleswi bed
ofthe useofbiomarkers andpharmacokinetics in riskassessments forbothcarcinogenesisandothereffects.
Introduction
Thereis aninescapableconnectionbetweentheconstruction
of dynamic models of pathological processes and the use of
biomarkers, parametersthatputatively represent somestepalong
thecausalpathwaybetween exposureandeffect. hnplicitly orex-
plicitly, any useofabiomarkerin ariskassessmentrequires one
to make some sets ofquantitative dynamic assumptions about
both the relationship between exposure and thebiomarker and
therelationshipbetweenthebiomarkerandtheultimatehealth
consequences ofinterest. Atthe sametime, anyconstructionof
a dynamic model for use in risk assessment must remain a
theoreticalexerciseuntilspecificpredictionsabouttherelation-
ships ofintermediate parameters to exposure and/oreffect can
be verified.
Philosophy of Science Issues
There are threebasic reasons why itis desirable to useboth
models andmarkers to open uptheblackboxbetween exposure
andeffect. The useofmodelandmarkersa)leadtoa more com-
pletescientificunderstanding andincorporate morerelevantin-
formationaboutcausal mechanismsthan asimpleinput-output
analysis; b) offers the eventual prospect ofbetter mechanism-
based projection of risk beyond the range of possible direct
observations; andc) offers thepossibility ofgreater sensitivity
ofdetectionandquantification ofadverseeffects in some cases,
going from the organism to the cell as the unit ofanalysis.
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Realizing the potential of both biomarkers and pharmaco-
kinetic modeling, however, requires overcoming some
philosophical assumptions that are common in the scientific











based representations ofcomplexbiological processes. In any
event, doingsowouldcomplicatetheuseoftheirusualblackbox
curve-fittingapproachestoanalysis, introducingmorevariables
than can be directly estimated from any single data set and
thereforerequiringrelativelyinnovative(fromastatisticalstand-




and theory, analysis can be as fruitful in producing new






Able 1. Examplesoftheuseofinr ate parmeters ("binarkers") in risksforvariousendpoints.
Agent Intermediateprameter Ultimate endpoint Reference
Perchloroethylene Metabolizeddose/body weight 3X Carcinogenesis (3)
Butadiene Metabolizeddose/body weight 3X Carcinogenesis (4)
Ethylene oxide Internal concentration X time Carcinogenesis (S)
Acrylamide Accumulated damage (inhibition ofretrograde ax- Neurotoxic effects fromdyingbackaxonopathy (6)
onal transport?)
Glycol ethers Sperm count Reduced malefertility (7,8)
Glycol ethers Birth weight Infantmortality (9)
Acid particles Particle numberdeposited intracheobronchial (Possible contributions tochronicbronchitis?) (10)
regionwithsufficient acid content















wewouldultimately liketoknow aboutthequantitative causal
relationshipsimplied, or, themarkersandmodelsarefullyscien-
tifically validated. Rather the tests that should be applied in
decidingwhetheraparticularmodelormarkerisapropriate for
provisional use in risk assessment are: a) Does the model or
marker, byincorporatingadditionalrelevantinformationonlike-
lycausalprocesses,helptobetterclarifythe"rangeofnotclearly










the detailed analysis issues. The full reports tend to be book-
lengthdocuments, whicharedifficulttopublishintheshortened
form required by most scientific journals. The length of full
reportsresultsfromanattempttoexplorenewmethodology, and
because to servethedecision-making functionoudinedabove,
thestudies mustincludeextensiveanalysesofthesensitivity of
theconclusions todifferentstructuralassumptions andplausi-
blevalues ofkeymodelparameters. Veryoften, allthis simply
willnotfitwithin20pagesevenforonestudy, anditisevenless
feasible todothis fortherangeofstudies listed inTIble 1.





of better measures of the internal dose of DNA-alkylating
substances at different external exposure levels, we hoped to
avoidattributinghigh-dosepharnacokineticnonlinearitiestothe
fundamental multiple mutation mechanism ofcarcinogenisis.
Anothergoalofthesestudieswastoimproveinterspeciesprojec-
tionofrisk.
The perchloroethylene and butadiene analyses attempt to
quantifythemetabolismofthesesubstancestoactiveepoxy in-
termediates, thustheintermediateparameterofinterestisafunc-
tion ofmetabolized dose. By now the basic structure of such
models, where high-dose nonlinearities are assumed to result
fromsaturationofasingleliverenzymewithMichaelis-Menten
enzymekinetics(Fig. 1) isrelativelyfamiliar. Forethyleneox-
ide, apreformedepoxidealkylating agent, thechallengewasto
determine the rates of detoxifying metabolism for different
speciesandatdifferentexposureratesandthusquantifythein-
ternal dose x the substanceavailable for DNA reaction.
In the cases of perchloroethylene and ethylene oxide, the
metabolismmodelswerecalibratedwiththeaidofindependent
dataforallthree speciesofinterest(mice, rats,andhumans). One
necessarycaveat,however, isthattheimportantissueoftheap-
propriate dosemetric forriskperunitofactive metabolites x
time afterpharmacokinetic analysis is still not settled. Forthe
best-estimatesofrisk, ametabolizeddose/(bodyweight)M' pro-
jection rule is used because this best fits the rat/mouse car-
cinogenic risk data for perchloroethylene and because it con-





















FIGURE 1. Basic rat perchloroethylene pharmacokinetic model with administration by gavage.
and co-workers (14), theexpectation was for ahalf-life of28.4
min. Martinetal.'sactualfindingswerehalf-livesof29.3 ± 5.7
minand36.5 + 18.5 min(SD)afterIVadministrationof25 and
75 mg/kg dose levels.
Oneoftheimportantlessonsfromourworkwasthehighfre-
quency withwhichwefounditnecessarytomodifyorelaborate
the standard pharmacokinetic model design represented in
Figure 1 to accommodate the facts and data types available in
specificcases. Anearlierreport(15), described somedistinctive
features ofour human perchloroethylene models that were re-
quiredtoaccommodate boththeextensivealveolarairexhalation
data ofStewart et al. (16) and the metabolite urinary excretion
dataforhumanworkers. Furtherunanticipatedassumptionswere
required to interpret data from available metabolic disposition
experiments inanimals: assumptionsaboutgastrointestinal ab-
sorption rates were required for interpretation of gavage ex-
periments, andassumptionsabouttherateoflossofmetabolized
material wererequired forinterpretationofexperimentsinwhich
thecompound wasadministered by inhalationoveranextended

















straightforward. However, thereweretwomajorsurprises. The
firstmajorsurprisewasthatratabsorptionandexcretiondatafor
ethylene oxide (19) were only interpretable, whatever model
structureandparameterswetried, ifbreathing ratesdeclinedat




of an irritant gas would tend to reduce respiration. Here,
however, is another case where only our modeling revealed a
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FIGuRE2. Conceptual model ofethyleneoxidemetablismintheliver.
primary implication ofthedataand, ofcourse, thedesirability
ofhavingmeasurements, rather than aneedtoestinmae,thisim-
portant constant, which turned out tobe avanable.
The second surprise that caused us to even more radically
restructure ourethyleneoxide model was anextensivebody of
evidenceofglutathionedepletionin diferent orgnsathighdose
rates (22). This in itself would be expected to decrease the
metabolism rateofethyleneoxide athighdoseswhether or not
there wasalso saonofany meabozing enzymes thatmight
be involved incatalyzing the reactions. Because wehad no in-
dependentevidenceofenzymesaturation, wedecided to seeif
models based solely on glutathione depletion as amechanism
producinghigh-dosenonlinearitieswouldbecompatiblewiththe
available data.
As it happened, they were. Constructing such models,
hower, required, foreachorgan/organ groupinvolved, seting
up a baseline model ofglutathione generation and loss, in the
lightofavailabledata onglutathioneequilibriumlevelsandtur-
nover(23,24). Thebasicconceptualmodelforthissysteminthe
liver is diagrammed in Figure 2, where k2 is the rate of the
bimolecular reaction between ethylene oxide andglutathione,
andkl isthe fractionoftotalethyleneoxidemetabolismthat is
accounted for by glutathione. These were the adjustable
parameters intheethyleneoxidemodels, withtheconstrint, for
theinitial models, thatk2 andkl were keptuniform acrossdif-
ferentorgans. Differentsetsofdatawereusedtosetthevaluesof
theadjustablea esfordifrspecies:a)Forrats,weused
the data ofTylerand McKelvey (19) onabsorptionofethylene





assessmentofexposure forthesedata, andother needed inter-
pretiveassumptons, renmeruchmoreuncertainforourpur-
poses than the Brugnone etal. data.] c) Formice, weused the
hemoglobinaddc tobseratnofSegerback(27)andOstrman-
Golkaretal. (28)fohlowing iP ir oflow doses. Given
thesemetbolismrates, low-dosealveolarventilation rates were
set to reprduce theabsorption dataofEhrenberg etal. (29).
After the initialseriesofmodels wereconstructed, ratmodel
predictions were compared with the high-dose glutathione-
depletion data of McKelvey and Zemaitis (22) and the
hemoglobinadductdataofOserman-Golkaretal. (30). Forthe
finalmodels,itwasfoundthathavingk2betwice aslargeinthe




Mmre our experience with the animal inhalation data for per-
chlorethylene: itwaspossibleformetabolized matrialtobelost
priortotheplacementofanimalsinmetabolismcagesattheend
ofexposure. Tlwoearlier risk assessments forbutadiene(31,32)
usedastheirmeasureofdoseinanimals,theamountofbutadiene
retained attheendof6-hrexposuresinexperiments byBondet
al. (33). Tothedegreethatbutadiene wasprocessedandactive





therefore escapes activating metabolism) the delivered dose
wouldbeoverestimated.
Tocalibrate ourmetabolismmodelsinthis case, weusedin-
ferencesfrombutadienechamberabsorptionstudiesofKreiling
etal. (34)andbloodbutadiene measuranentsfromtheBondet
al. (33)data set. Todothis, wefoundthatit wasimpossiblefor
allmetabolism tobeoccurring intheliver. Inthis case, even if
allofthebloodflowingtotheliverinratsandmiceweretohave
beencompletelyclearedofbutadiene, themetabolic elimination
wouldstill nothavebeensufficient to accountfortheobserved
rate ofbutadiene metabolism. This, combined with the direct
observationsofSchmidtand Loeser(35)ofsubstantialbutadiene
metabolism by lungtissue, caused us tocombinethe liver and
vessel-richtissue groups(includingthekidney, etc.)inourbuta-
dienemodelsto allowthegreaterbloodflowtothelattertissues
to be exposed to our models' metabolizing enzymes. The
resultingmodelsdidindeed indicatethatappreciablebutadiene
waslikely tohavebeenlostpriortomeasurementintheBondet
al. experiments, and that moreover, the estimates of human
delivereddoseusedintheriskassessments werelikely tohave
been appreciably overstated.
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'AI data in lifetim risks foroccupational exposure to I ppm, 8-hr/day, 5
dasweekfor45 years.
'ND, notdone. Implicitlyabestesma equivalet toalifetime riskof0.104
ws a omt dl hmanl Ias intheHosedtstudy(37).
Thisis acentrltndencyestimatebecause nostatstca upperconfidecelimit






tainties in thepharmacokinetics/metabolism and conventional
uncertainties inprojection ofhuman risks from animal data.
Forexample, thebestestimate numbers reflecta) maximum
likelihood estimates ofconventional multistage dose-response
relationships inanimals (modifiedinonebutadienedatasettoac-
count for possible interactions between butadiene-induced
mutagenictransitions andsimilartransitionscausingbackground
cancers in humans); b) the geometric mean ofrisk determina-
tions indifferentspeciesandsexgroupsinanimals; c)ananimal-
to-humanprojection ofriskdepending ondose/(bodyweight)3A
andd)thebestestimates ofmetabolic formation fromanimaland
human pharmacokinetic models. The plausible upper limit
numbers reflecta) the upper 95% confidence limit estimate of
the linear tenn ofmultistage dose response models; b) the car-
cinogenesis experience of the most sensitive species and sex
tested; c) ananimal-to-human projection ofriskdepending on
dose/(bodyweight)6; andd)esimatesofhumandosein relation
toanimal dosederived fromourplausible upperlimit versions
ofourhumanpharmacokinetic models. Comparing ourplausi-
bleupperlimit results withthose ofEPA, itcanbe seenthatthe
modeling sometimes increases and sometimes decreases the
final upperboundestimatesofrisks, although inall three cases
ourleastunlikelyestimatesarebelowEPA'supperboundfigures.
In conclusion, pharmacokinetic analysis is nobody's unam-
biguous, quick solution to the problem of uncertainty in
carcinogenic riskanalysis. Each ofthemodels Ihavedeveloped
to date need to undergo serious structural modification in the
light ofthe data available for the specific case. The process of
doing these modifications is adeveloping art, requiring liberal
doses ofjudgment ratherthancookbook formulas. Inaddition,
the models raised as many interesting questions as they ans-
wered, often revealing unsuspected sources ofuncertainty and
nonobvious difficulties in fairly assessing the extent of the
uncertainties.
As often as not, thepharmacokinetic analysis does not make
amajordifferenceinthefinalnumericalprojectionofrisks(par-
ticularly ethylene oxide). The exception is butadiene, where
nbke Elemntsofanewanlysis fornoncancer heatheffect medited
by a"fanctional intermediate" parameter.
1. Elucidate the quantitative relationships betwn internal dose/tim oftoxicant
exposure andchange inthe functional intermediate parameter.
2. Assess thepreexisting backgrounddistribution ofthefunctional intrmediate
parameter in the human population.
3. Assess the relationship between the functional intermediate parameter and
diminished physiological perfornance and/or adverse health effects.
4. Assess themagnitude ofparameterchanges likely to result from specific ex-
posures inhumans (taking into account human interindividual variability in
themetabolismand otherdeterminants ofpharmacokinetics) andconsequent
changes in the incidence and severity ofhealth effects.
0. Do not attempt, from the biology alone, to determine acceptable levels of
parameter changeorexposure. (Letthe policy makersdecide what changes
intheincidenceand severity ofhealth effects are acceptable inthe contextof
themodesofexposureand inthe lightofthefeasibility ofreducingoravoiding
the exposure.)
there was nearly an order-of-magnitude effect. Nevertheless,
thereishopethatinlongrun,pharmacokineticanalysiscanboth
facilitate the process of asking better and more relevant ex-
perimental scientific questions and helpmake riskassessment
models somewhat better in the sense of incorporating more
realistic andmoreexperimentally testableinformationaboutthe











tion as has recently become standard for cases ofcancer. We
believe thattheusualno-observed-effectlevel/safety factorap-
proachhasseriouslimitations, bothfromascientific standpoint
and for the needs of social decision making. Table 3 gives an
overview ofthe kinds ofanalyses we believe scientists should
seektodevelopasareplacement, atleastforthoseefietsthatcan




damage processes are defined as those that are fundamentally
reversible, atleastinpre-clinical stages, butthattakearelatively
long time (weeks or months) for reversal/repair tooccur (38).
This applies tosome, butpossibly not all (39), ofacrylamide's
neurotoxiceffects. Riskassessments forthesechemicalsneedto
address anumberofsignificantissues: a) Whataretherelation-
ships between external dose and the generation ofthe internal
damage/toxicant accumulation? b) What are the nature and
dynamics ofreversal ofthe slow step in the process that makes
theprocesschronic? c)Whatarethedifferencesamongspecies
in both the generation ofdamage/toxin accumulation and the
repair/reversal process? d) How much interindividual variation
can be expected among exposed people in both damage-
producing and repairprocesses (and therefore susceptibility to
toxicity)?
Theacrylamide caseisinteresting inthatitindicatesthepoten-
tial helpfulness ofan entirely theoretical modeling exercise in
basictoxicologicalresearch. Ascanbeinferred fromTable 1, we
donotknowtheexactphysical formoftheincipientdamagethat
accumulates over weeks or months to ultimately lead to the
grosser manifestations ofperipheral neuropathy. In the caseof
acrylamide, three decades of experimental observations have
yielded an extensive characterization ofneuropathic effects at
boththemorphological (40) andfunctional levels (41). Atthekey
biochemical/molecular level, however, there is analnostembar-
rassing richness ofcandidates forcausal intermediateprocesses
inthegenerationofneurological damage. Among the mostpro-
minent ofthese are inhibition ofretrogrde transport systems
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Table 4. Data of Fuflerton and Barnes (45) on dose/time response for
development ofhindlimbweknessinrats













(which convey material from the axons back to the cell body)
(42,43). A number of other mechanisms have also received
serious study.
For our modeling work, we elected to return to someofthe
mostclassicalstudiesofacrylamideneurotoxicity (44-46)and
apply a simple dynamic analysis model to them. Thedata sets
analyzed are those that have provided information on some
specific manifestation oftoxicity produced by different com-
binations of acrylamide dose rate and duration of exposure





of the the incipient damage, i. e., how much of the past ac-
cumulateddamageisrepaired perday?Howdoes thiscalculated
repair rate appear to change a) across species, and b) for dif-
ferent adverse effect end points, with different amounts of
calculated accumulateddamage? Thesecondpieceofinforma-
tionis thedoseofacylamidethatwouldbejustbarelyabletopro-
duce each effect in each species if the experiment were con-




and in different species with the dynamics that are consistent
with the repair rates calculated from the dose versus time-of-
effect data.
Our model for analyzing acrylamide data (Fig. 3) is built
aroundthreeassumptions: a) Aparticularadverseeffect occurs
whenever a specific amount ofdamage is accumulated in the
relevantportionsofthe nervous system. Thereis noappreciable
delaybetween theproductionofdamageand themanifestation
oftheresulting effects. b) Damage isproduced at a rate thatis
ACCUM_DAMAGE
DAMAGE-PROD REPAIR
FIGURE 3. Model ofacrylamide damage accumulation and repair.
approximatelylinearwiththemilligramperkilogramdosead-
ministeredtotheanimals. c)Repairoftheaccumulateddamage
occurs at a rate that depends direcdly on the amount of ac-
cumulated damagethatthereis toberepaired.
The first assumption provided us with our primary tool for
quantitatively analyzingthedata. Basically, bytrialanderror,








ty used an analysis ofthe pharmacokinetics ofethoxyethanol
(EE)anditsmetabolite, ethoxyaceticacid(EAA), tohelpinter-
pretobservationsofEAAexcretionand spermcountdistribu-
tions in recent studies oftwo groups ofworkers with EE ex-
posure and concurrent controls (47-49). Based on existing
observationsofrelationshipsbetweenspermconcentrationsand
malefertilityperformance [whicharenotwithoutcontroversy
among andrologists (50)], we assessed the likely results of
observed changes in sperm count distributions in the worker
groups in two kinds ofunits: the increase in the numbers of
couples expected toexperiencea sufficientdelay inachieving
pregnancytoseekmedicaltreatment[analysisafterthemethod
ofMeistrichandBrown(51)]; andtheincreaseinthemonthly
probability ofachieving thepregnancy [with a female partner
drawn from a particular population, based on data from
Steinbergerand Rodriguez-Rigau (52)].
Tables 5 and6 show thesedifferentperspectives on the im-
plications ofthe changes in sperm count distributions in this
case. TheassumptionsfromMeistrichandBrown(51)underly-
ing the calculations in Table 5 area) a uniform multiplicative
sperm reduction effect across the entiredistribution ofsperm
counts, b)alinearrelationshipbetweenthemultiplicativespenn
















ofdata (53,54) seemed to be compatible with a linear dose-
responserelationship(Figs. 4and5). Mechanistically, itseems
possiblethatarapidlygrowingorganism, usingessentially all
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Table 5 Projeionsofinfertili risk asafunction ofdose, basedonMeistrich andBrown(5) assumptions.2
Geometric meandose, ppm Doseexceeded5% oftime % Spermcount reduction "Reduction factor" Excess "infertiilty risk"
Calculations basedonthe shipyard painterfindings (forthegroupexposed over0.8ppm)
Averages overseveral dys to aweekb
0.89 2.6 5.70 1.06 0.25
1.72 5.0 10.80 1.12 0.50
3.28 9.6 19.40 1.24 1.00
4.9C 14.3C 27.5c 1.38c 1.58c
5.97 17.4 32.40 1.48 2.00
Calculations based onOregon Foundry Worker findings
4.98 5.70 1.06 0.25
9.70 10.80 1.12 0.50
12.8c 14 1.16c 0.67c
18.30 19.40 1.24 1.00
33.23 32.40 1.48 2.00
'AsdefinedbyMeistrich andBrown(51), the "riskofinfertlity" istheincreaseintheprobability thatacouplewillhaveasufficientdelay inachieving conception
toconsultaphysician fordiagnosis. Ethoxyethanol andethoxyethanol equivalentpartspermilliondosagecalculated fromurinaryethoxyaceticacidexcretionus-
ingthebestestimatepharmacokinetic model. Tocalculateequivalentmethoxyethanoldosage, thepartspermillionequivalentsinthistimetableshouldbedivided
by 4.3.
t)Thevariability forshorteraveraging times wouldbegreater, andhencethedifference betweentogeometric meanexposure andtheexposureexceeded5% of
the time wouldbegreater.
CThesedatarepresenttheestimateddosageand meansperm countreductionsobserved intheactualepidemiological data. Dataonotherlinesofthetablerepre-
sentprojections using the Meistrich and Brown (51) assumptions.
Table6. Impctnsofa 1.24-foldreductioi' inspermcountsforincreas inthetimes requiredforcouplestoconceive.
Motile Percycle Number ofmonthly cycles needed fordifferent
spermcount conception percentages ofcouples toachievepregnancy
millions/mi probability 20% 50% 80% 90%
Base case (no sperm count reduction)
10 0.027 8.2 25.4 58.9 84.2
20 0.042 5.2 16.3 37.7 54.0
40 0.065 3.3 10.4 24.1 34.5
80 0.100 2.1 6.6 15.3 21.8
160 0.155 1.3 4.1 9.6 13.7
Sperm counts reducedby 1.24-foldb
8.1 0.024 1.2 3.7 8.7 12.4
16.1 0.036 0.8 2.4 5.6 8.0
32.3 0.056 0.5 1.6 3.6 5.2
64.5 0.087 0.3 1.0 2.3 3.0
129.0 0.135 0.2 0.7 1.5 2.2
'Correspondingtoapproximatelya 1% increase, fromabout 15% to 16%, inthepercentageofcoupleswhohave asufficientdelay inachievingconception to lead
themtoconsult aphysician fordiagnosis.
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Foun 4. Responseofnxmus fetal weights to gavage adminiso ofethy- FIGutE 5. Responseofrabbitfetal weights todaily exposure ethylene glycol
leneglycol ethyl ether. Data fromWeir etal (53). methyl ether. Data from Hanley etal. (54).







y = 39.488 - 7.2069e-2x R^2 = 0.996
60
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I3ble7. VAightdifferences betweenblackandwhite newborns atdifferent permentilesofthebirthweight distributions.'
Weights atdifferentpercentiles, g gdifference,
All 1980 All 1980 Weight % Weight averageweight
Percentile whites blacks difference, g reduction difference
1 1691.8 988.7 703.1 41.56 2.569
2 2090.1 1465.4 624.8 29.89 2.283
5 2507.1 2080.2 426.9 17.03 1.560
10 2738.5 2432.3 306.2 11.18 1.119
30 3168.7 2909.4 259.3 8.18 0.948
50 3424.0 3180.3 243.7 7.12 0.891
70 3673.7 3434.3 239.4 6.52 0.875
90 4040.0 3821.8 218.2 5.40 0.797
95 4263.1 4012.3 250.7 5.88 0.916
98 4514.1 4276.4 237.8 5.27 0.869
99 4523.2 4362.7 160.6 3.55 0.587
Overall average 3411.9 3138.2 273.6 8.02
aData from Hogue etal. (55).
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FiGuRE 6. Weightdistributions forblack andwhite singletoninfantsborn in
1980.
the available metabolic energy it can muster to grow and dif-
ferentiate, mightwellhavelittleornofunctionalreservecapaci-
ty. Thus, evenmarginaladditionalstressesmightcauseeffects
without having a true threshold dose that could be absorbed
without producing at leastamarginal adversechange.
Iftheindicatedchangeinfetalweightsinanimalsweretobe
paralleledbyachangeinaveragebirthweightsinhumans, there
could be an effect on infant mortality, which is very strongly




ly assume that the entire human distribution ofbirth weights
receivesthesamemultiplicative reduction inweight. To seeif
this was areasonablemodelofbirth weightchangeinhumans
exposedtoanarrayofdifferentstressors, wehaverecentlycom-
pared the population distributions of all black and all white
singletonbirthsfrom 1980(Fig. 6, Table7). Overall, itcanbe
seeninFigure6thatbothblackandwhitebirthweightdistribu-
tionstendtobebimodal, withthelowermodeincluding2.5 to









tionsassociated withmoredefined stressors (such as smoking
andalcohol) toseewhatpatternsofbirthweightchangemight
be indicated for different agents and whether accompanying
changesininfantmortalityfromtheseagentsarewellpredicted








ble social consequences fordifferent risks ifspecific relation-
shipsbetweenexposures, intermediateparameters, andendef-
fects weretotakeon specific, reasonably likely forms.
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